Medicaroid Corporation and Medicaroid Asia Pacific Pte. Ltd. have announced that regulatory approval has been received from the Health Sciences Authority in Singapore for the hinotori Surgical Robot System on September 13.
The hinotori is a made-in-Japan robotic-assisted surgery system which received a regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) in August 2020. Since its launch in December of the same year, it has been used in a number of medical institutions and the number of cases performed is over 2,000.
Along with the domestic Japan business, Medicaroid has been preparing for business expansion in the global market. In October 2022, Medicaroid Asia Pacific Pte. Ltd., a subsidiary in Singapore was established to serve as a base for activities in Southeast Asia, Oceania, and South Asia. On April 28, 2023, an application for regulatory approval for the hinotori was submitted to the Health Sciences Authority (HSA) and the approval was granted. This is the first overseas regulatory approval of the hinotori.
In Singapore, the hinotori will be used in urology, gastroenterology and gynecology, as these procedure types are also approved in Japan. With this approval, Medicaroid, together with Medicaroid Asia Pacific Pte. Ltd. and the general agent Sysmex Corporation, will prepare for sales activity in the Singapore market.
Through its medical robots, Medicaroid will continue to support an abundant society where all patients, patients’ family, and healthcare workers can live with peace of mind.
Reference: Regulatory Approval Application Filed with the Health Sciences Authority in Singapore for the “hinotoriTM Surgical Robot System”